MICHAEL PEACOCK: Open Payments
NPI 1487636742 · EASTMAN, GA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,935 in 60 payments from 17 companies in 2025. Trend: 2023 $846 · 2024 $1,160 · 2025 $1,935
Food & beverage: $1,854Education: $81
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 19 | $692 |
| Otsuka America Pharmaceutical, Inc. | 15 | $489 |
| SK Life Science, Inc. | 2 | $157 |
| Teva Pharmaceuticals USA, Inc. | 2 | $104 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $103 |
| Lundbeck LLC | 5 | $93 |
| UCB, Inc. | 3 | $70 |
| Esperion Therapeutics, Inc. | 2 | $30 |
| AstraZeneca Pharmaceuticals LP | 2 | $28 |
| Bayer Healthcare Pharmaceuticals Inc. | 1 | $24 |
Products named: REXULTI, INGREZZA, Briviact, Nayzilam, NEXLETOL, Kerendia, Zunveyl, AUSTEDO XR.
Industry payments across GA — which companies pay providers there.
